 Context Therapeutics NASDAQ:CNTX has announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended-release ONA-XR, the companys novel, first-in-class, potent, orally administered progesterone receptor PR antagonist, in metastatic breast cancer. Being conducted in collaboration with the Wisconsin Oncology Network, the Philadelphia-based womens oncology company said the Phase 2 SMILE trial is evaluating ONA-XR in combination with fulvestrant in patients with ER estrogen receptors, HER2- human epidermal growth factor receptor 2 advanced or metastatic breast cancer who progressed on prior CDK46 inhibitor therapy. 